Literature DB >> 2402776

Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients.

T Kickler1, S D Kennedy, H G Braine.   

Abstract

The rate of alloimmunization to platelet-specific antigens associated with platelet glycoproteins (GPs) IIb-IIIa and Ib/IX was studied in 293 multiply transfused thrombocytopenic patients. Antibodies to platelet-specific antigens were measured with a solid-phase assay using platelet GP IIb-IIIa or Ib/IX as the antigenic targets. Nine patients were found to have antibodies to platelet GP IIb-IIIa, and no patients had antibodies to platelet GP Ib/IX. In six of these nine patients, the specificity of the antibody was shown by using GP IIb-IIIa from donors with different platelet-specific antigen phenotypes. In the remaining three patients with antibodies to platelet GP IIb-IIIa, no specificity could be identified. These patients had autoimmune thrombocytopenia in association with lymphoma. The alloimmunization rate to platelet-specific antigens associated with GP IIb-IIIa was 2 percent, whereas the rate of alloimmunization to HLA antigens was 23 percent. Of the patients alloimmunized to HLA antigens, 9 percent also had antibodies to platelet-specific antigens. A poor response to HLA-identical platelet transfusions was observed only in those patients with positive assays in the solid-phase test. These results suggest that the incidence of antibodies to platelet-specific antigens carried on GP IIb-IIIa is low. Platelet-specific antibodies may be found more frequently in patients alloimmunized to HLA antigens than in those not so alloimmunized.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2402776     DOI: 10.1046/j.1537-2995.1990.30790385520.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

1.  Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.

Authors:  Ross M Fasano; Ewelina Mamcarz; Sharon Adams; Theresa Donohue Jerussi; Kyoko Sugimoto; Xin Tian; Willy A Flegel; Richard W Childs
Journal:  Br J Haematol       Date:  2014-04-18       Impact factor: 6.998

2.  Allogeneic major histocompatibility complex antigens are necessary and sufficient for partial tolerance induced by transfusion of pathogen reduced platelets in mice.

Authors:  Johnson Q Tran; Marcus O Muench; John W Heitman; Rachael P Jackman
Journal:  Vox Sang       Date:  2019-02-07       Impact factor: 2.144

3.  Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Sakura Hosoba; Edmund K Waller; Neeta Shenvi; Michael Graiser; Kirk A Easley; Zaid Al-Kadhimi; Akira Andoh; Ana G Antun; Sheliagh Barclay; Cassandra D Josephson; Jean L Koff; H Jean Khoury; Amelia A Langston; James C Zimring; John D Roback; Cynthia R Giver
Journal:  Biol Blood Marrow Transplant       Date:  2018-01-04       Impact factor: 5.742

Review 4.  Platelet transfusion refractoriness: how do I diagnose and manage?

Authors:  Claudia S Cohn
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

5.  Low-level HLA antibodies do not predict platelet transfusion failure in TRAP study participants.

Authors:  Rachael P Jackman; Xutao Deng; Douglas Bolgiano; Mila Lebedeva; John W Heitman; Michael P Busch; Sherrill J Slichter; Philip J Norris
Journal:  Blood       Date:  2013-02-07       Impact factor: 22.113

6.  Pooled platelet concentrates provide a small benefit over single-donor platelets for patients with platelet refractoriness of any etiology.

Authors:  Ying-Hsia Chu; William Nicholas Rose; William Nawrot; Thomas J Raife
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

7.  Using genome editing to engineer universal platelets.

Authors:  Moyra Lawrence; Annett Mueller; Cedric Ghevaert
Journal:  Emerg Top Life Sci       Date:  2019-05-31

Review 8.  Process analysis of pluripotent stem cell differentiation to megakaryocytes to make platelets applying European GMP.

Authors:  Moyra Lawrence; Amanda Evans; Thomas Moreau; Marta Bagnati; Matthew Smart; Enas Hassan; Jahid Hasan; Monica Pianella; Julie Kerby; Cedric Ghevaert
Journal:  NPJ Regen Med       Date:  2021-05-26

9.  Applicability of an instrument to identify human leukocyte antigen-compatible donors for platelet transfusions.

Authors:  Millena Gomes Ferreira; Fernanda Bernadelli De Vito; Aline Aparecida Ferreira; Carolina Bonet Bub; Fernando Antônio Vinhal Dos Santos; Adilson Botelho Filho; Sheila Soares Silva; Helio Moraes-Souza
Journal:  Hematol Transfus Cell Ther       Date:  2018-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.